Johnson & Johnson Reports Q2 2024 Financial Results and Updates Guidance

Details

The company also announced an earnings per share (EPS) decrease of 5.9% to $1.93 due to one-time special charges, but adjusted EPS increased by 10.2% to $2.82. Johnson & Johnson updated its full-year 2024 operational sales guidance to reflect the acquisition of Shockwave Medical, and its adjusted operational EPS guidance was updated to reflect improved performance, though costs from recent acquisitions offset some of the improvement. The company highlighted progress in its product pipeline, including regulatory milestones for RYBREVANT and TREMFYA, and the integration of Shockwave. Additionally, Johnson & Johnson announced several acquisitions and regulatory updates.

Items reported

Exhibits (2)

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.